Category - News

Markets

Raymond James sees Profound Medical insulated from COVID-19 fallout

Raymond James reiterated that Profound Medical (TSX:PRN; NASDAQ:PROF) remains its “analyst current favorite” and “2020 Best Pick,” saying Profound is “particularly insulated from the current economic fallout of COVID-19...

March 12, 2020

Developments

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...

March 12, 2020

Developments

Bee Vectoring kick starts U.S. west coast expansion

Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) closed three new grower deals with berry producers in Oregon and Washington states to use the company’s proprietary bee delivery system, VECTORITE...

March 11, 2020

Markets

BTIG ups Castle Biosciences PT to $41 from $32

BTIG raised its price target for Castle Biosciences (NASDAQ:CSTL) to $41 from $32 after the company reported fourth quarter results and initial revenue guidance for 2020. The stock closed at $29.36 on March 10. Castle...

March 11, 2020

Developments

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Albireo Pharma (NASDAQ:ALBO) completed patient enrollment in its Phase 2 trial of elobixibat for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The trial enrolled 47...

March 10, 2020

Developments

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

According to the FDA, the passage of the 2018 Farm Bill has led to the misperception that all products made from or containing hemp, including those made with cannabidiol (CBD), were now legal to sell in interstate...

March 10, 2020

Markets

HCW halves Tracon Pharma PT to $6 from $13

H.C. Wainwright slashed its price target for Tracon Pharmaceuticals (NASDAQ:TCON) to $6 from $13, but reiterated its “buy” rating, after the company and partner, Santen Pharmaceutical, discontinued development of DE-122...

March 10, 2020

Markets

HCW starts electroCore at buy; PT $2

H.C. Wainwright initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $2 price target. The stock closed at 65 cents on March 9. electroCore is commercializing its lead product, gammaCore, the only FDA...

March 10, 2020

Markets

HCW starts Corvus Pharma at buy; PT $10

H.C. Wainwright launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and $10 price target. The stock closed at $2.72 on March 9. Corvus is focused on developing precision medicines to treat...

March 10, 2020

Developments

Imagin Medical gets additional positive physician feedback on i/Blue Imaging System

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) has continued to collect additional input on its i/Blue Imaging System from physicians in the United States and Canada. Leading urologists...

March 10, 2020

Category - News

Raymond James sees Profound Medical insulated from COVID-19 fallout

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Bee Vectoring kick starts U.S. west coast expansion

BTIG ups Castle Biosciences PT to $41 from $32

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

HCW halves Tracon Pharma PT to $6 from $13

HCW starts electroCore at buy; PT $2

HCW starts Corvus Pharma at buy; PT $10

Imagin Medical gets additional positive physician feedback on i/Blue Imaging System

General

More